Last reviewed · How we verify
Cerebrovascular disease
Approved treatments
- 4-(O-Benzylphenoxy)-N-Methylbutylamine
BIFEMELANE works by inhibiting the enzyme Amine oxidase [flavin-containing] A, which plays a role in the breakdown of certain neurotransmitters. - Benzcyclan
Bencyclane works by relaxing blood vessels and improving blood flow to the brain. - Nafronyl
Nafronyl works by interacting with the 5-hydroxytryptamine receptor 2A to improve blood flow and reduce vascular resistance. - Vasodil · Novartis
- Praxilene · Merck Serono (originally Lipha)
A 5-HT2 receptor antagonist that improves peripheral blood flow and cellular metabolism by blocking serotonin-mediated vasoconstriction and enhancing aerobic metabolism in ischaemic tissues.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cerebrovascular disease patent landscape — cliff calendar, originator estates, attackable patents
- Cerebrovascular disease treatment landscape brief
- Cerebrovascular disease treatment updates RSS
Frequently asked questions about Cerebrovascular disease
What drugs treat Cerebrovascular disease?
Tracked treatments include 4-(O-Benzylphenoxy)-N-Methylbutylamine, Benzcyclan, Nafronyl, Vasodil, Praxilene.
What is the treatment for Cerebrovascular disease?
Standard treatment for Cerebrovascular disease includes 4-(O-Benzylphenoxy)-N-Methylbutylamine, Benzcyclan, Nafronyl, Vasodil, Praxilene. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cerebrovascular disease patent cliff · Cerebrovascular disease CI report
- Treatment: 4-(O-Benzylphenoxy)-N-Methylbutylamine
- Treatment: Benzcyclan
- Treatment: Nafronyl
- Treatment: Vasodil · Novartis
- Treatment: Praxilene · Merck Serono (originally Lipha)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing